{"entity":{"type":"insider","cik":"0001585699","url":"/insider/0001585699","json_url":"/insider/0001585699.json","name":"Mates Sharon","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":92,"n_filings":33,"first":"2014-11-28","last":"2024-12-06","span_basis":"filed_date"},"name_variants":[{"name":"Mates Sharon","source":"filing","n_filings":33,"first_seen":"2014-11-28","last_seen":"2024-12-06"}],"transactions":[{"id":2525512,"accession":"0000950170-24-134240","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000950170-24-134240","line_url":"/filing/0000950170-24-134240","is_derivative":false,"issuer_cik":"0001567514","issuer_name":"Intra-Cellular Therapies, Inc.","issuer_ticker":"ITCI","issuer_name_source":null,"issuer_url":"/issuer/0001567514","owner_cik":"0001585699","owner_name":"Mates Sharon","owner_display_name":"Mates Sharon","owner_url":"/insider/0001585699","role":"Director, Officer (Chairman and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chairman and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":51697.0,"shares_display":"51,697","price_per_share":84.0830514981527,"price_display":"84.08","price_state":"stated","total_value":4346841.5133,"total_display":"4,346,841.51","total_whole":"4,346,842","shares_owned_after":1071863.0,"shares_owned_after_display":"1,071,863","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-12-05","filed_date":"2024-12-06","scope":"insider","n_lines":2},{"id":2525501,"accession":"0000950170-24-134240","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-24-134240","line_url":"/filing/0000950170-24-134240","is_derivative":false,"issuer_cik":"0001567514","issuer_name":"Intra-Cellular Therapies, Inc.","issuer_ticker":"ITCI","issuer_name_source":null,"issuer_url":"/issuer/0001567514","owner_cik":"0001585699","owner_name":"Mates Sharon","owner_display_name":"Mates Sharon","owner_url":"/insider/0001585699","role":"Director, Officer (Chairman and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chairman and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":51000.0,"shares_display":"51,000","price_per_share":85.79724325098039,"price_display":"85.80","price_state":"stated","total_value":4375659.4058,"total_display":"4,375,659.41","total_whole":"4,375,659","shares_owned_after":1093662.0,"shares_owned_after_display":"1,093,662","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-12-04","filed_date":"2024-12-06","scope":"insider","n_lines":2},{"id":2897668,"accession":"0000950170-24-102475","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000950170-24-102475","line_url":"/filing/0000950170-24-102475","is_derivative":false,"issuer_cik":"0001567514","issuer_name":"Intra-Cellular Therapies, Inc.","issuer_ticker":"ITCI","issuer_name_source":null,"issuer_url":"/issuer/0001567514","owner_cik":"0001585699","owner_name":"Mates Sharon","owner_display_name":"Mates Sharon","owner_url":"/insider/0001585699","role":"Director, Officer (Chairman and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chairman and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":34396.0,"shares_display":"34,396","price_per_share":72.8384455634376,"price_display":"72.84","price_state":"stated","total_value":2505351.1736,"total_display":"2,505,351.17","total_whole":"2,505,351","shares_owned_after":1076522.0,"shares_owned_after_display":"1,076,522","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-30","filed_date":"2024-08-30","scope":"insider","n_lines":2},{"id":2897648,"accession":"0000950170-24-102475","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-24-102475","line_url":"/filing/0000950170-24-102475","is_derivative":false,"issuer_cik":"0001567514","issuer_name":"Intra-Cellular Therapies, Inc.","issuer_ticker":"ITCI","issuer_name_source":null,"issuer_url":"/issuer/0001567514","owner_cik":"0001585699","owner_name":"Mates Sharon","owner_display_name":"Mates Sharon","owner_url":"/insider/0001585699","role":"Director, Officer (Chairman and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chairman and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":35604.0,"shares_display":"35,604","price_per_share":72.5728661611055,"price_display":"72.57","price_state":"stated","total_value":2583884.3268,"total_display":"2,583,884.33","total_whole":"2,583,884","shares_owned_after":1076101.0,"shares_owned_after_display":"1,076,101","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-29","filed_date":"2024-08-30","scope":"insider","n_lines":2},{"id":2345261,"accession":"0000950170-24-101506","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0000950170-24-101506","line_url":"/filing/0000950170-24-101506","is_derivative":false,"issuer_cik":"0001567514","issuer_name":"Intra-Cellular Therapies, Inc.","issuer_ticker":"ITCI","issuer_name_source":null,"issuer_url":"/issuer/0001567514","owner_cik":"0001585699","owner_name":"Mates Sharon","owner_display_name":"Mates Sharon","owner_url":"/insider/0001585699","role":"Director, Officer (Chairman and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chairman and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":32699.0,"shares_display":"32,699","price_per_share":72.74843581149271,"price_display":"72.75","price_state":"stated","total_value":2378801.1026,"total_display":"2,378,801.10","total_whole":"2,378,801","shares_owned_after":1070569.0,"shares_owned_after_display":"1,070,569","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-28","filed_date":"2024-08-28","scope":"insider","n_lines":2},{"id":2345249,"accession":"0000950170-24-101506","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000950170-24-101506","line_url":"/filing/0000950170-24-101506","is_derivative":false,"issuer_cik":"0001567514","issuer_name":"Intra-Cellular Therapies, Inc.","issuer_ticker":"ITCI","issuer_name_source":null,"issuer_url":"/issuer/0001567514","owner_cik":"0001585699","owner_name":"Mates Sharon","owner_display_name":"Mates Sharon","owner_url":"/insider/0001585699","role":"Director, Officer (Chairman and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chairman and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":40513.0,"shares_display":"40,513","price_per_share":73.58269822772937,"price_display":"73.58","price_state":"stated","total_value":2981055.8533,"total_display":"2,981,055.85","total_whole":"2,981,056","shares_owned_after":1087185.0,"shares_owned_after_display":"1,087,185","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-27","filed_date":"2024-08-28","scope":"insider","n_lines":2},{"id":2345232,"accession":"0000950170-24-101506","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-101506","line_url":"/filing/0000950170-24-101506#line-2","is_derivative":false,"issuer_cik":"0001567514","issuer_name":"Intra-Cellular Therapies, Inc.","issuer_ticker":"ITCI","issuer_name_source":null,"issuer_url":"/issuer/0001567514","owner_cik":"0001585699","owner_name":"Mates Sharon","owner_display_name":"Mates Sharon","owner_url":"/insider/0001585699","role":"Director, Officer (Chairman and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chairman and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":22713.0,"shares_display":"22,713","price_per_share":74.5929,"price_display":"74.59","price_state":"stated","total_value":1694228.5377,"total_display":"1,694,228.54","total_whole":"1,694,229","shares_owned_after":1070329.0,"shares_owned_after_display":"1,070,329","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-26","filed_date":"2024-08-28","scope":"insider"},{"id":2117490,"accession":"0000950170-24-100275","txn_seq":10,"anchor":"line-10","filing_url":"/filing/0000950170-24-100275","line_url":"/filing/0000950170-24-100275#line-10","is_derivative":false,"issuer_cik":"0001567514","issuer_name":"Intra-Cellular Therapies, Inc.","issuer_ticker":"ITCI","issuer_name_source":null,"issuer_url":"/issuer/0001567514","owner_cik":"0001585699","owner_name":"Mates Sharon","owner_display_name":"Mates Sharon","owner_url":"/insider/0001585699","role":"Director, Officer (Chairman and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chairman and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":28680.0,"shares_display":"28,680","price_per_share":74.4573,"price_display":"74.46","price_state":"stated","total_value":2135435.364,"total_display":"2,135,435.36","total_whole":"2,135,435","shares_owned_after":1070329.0,"shares_owned_after_display":"1,070,329","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-23","filed_date":"2024-08-23","scope":"insider"},{"id":2117486,"accession":"0000950170-24-100275","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0000950170-24-100275","line_url":"/filing/0000950170-24-100275","is_derivative":false,"issuer_cik":"0001567514","issuer_name":"Intra-Cellular Therapies, Inc.","issuer_ticker":"ITCI","issuer_name_source":null,"issuer_url":"/issuer/0001567514","owner_cik":"0001585699","owner_name":"Mates Sharon","owner_display_name":"Mates Sharon","owner_url":"/insider/0001585699","role":"Director, Officer (Chairman and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chairman and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":39380.0,"shares_display":"39,380","price_per_share":74.67755167597765,"price_display":"74.68","price_state":"stated","total_value":2940801.985,"total_display":"2,940,801.98","total_whole":"2,940,802","shares_owned_after":1074698.0,"shares_owned_after_display":"1,074,698","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-22","filed_date":"2024-08-23","scope":"insider","n_lines":2},{"id":2117480,"accession":"0000950170-24-100275","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000950170-24-100275","line_url":"/filing/0000950170-24-100275","is_derivative":false,"issuer_cik":"0001567514","issuer_name":"Intra-Cellular Therapies, Inc.","issuer_ticker":"ITCI","issuer_name_source":null,"issuer_url":"/issuer/0001567514","owner_cik":"0001585699","owner_name":"Mates Sharon","owner_display_name":"Mates Sharon","owner_url":"/insider/0001585699","role":"Director, Officer (Chairman and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chairman and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":53013.0,"shares_display":"53,013","price_per_share":75.65127059211892,"price_display":"75.65","price_state":"stated","total_value":4010500.8079,"total_display":"4,010,500.81","total_whole":"4,010,501","shares_owned_after":1079208.0,"shares_owned_after_display":"1,079,208","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-21","filed_date":"2024-08-23","scope":"insider","n_lines":4},{"id":2543782,"accession":"0000950170-24-029583","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0000950170-24-029583","line_url":"/filing/0000950170-24-029583","is_derivative":false,"issuer_cik":"0001567514","issuer_name":"Intra-Cellular Therapies, Inc.","issuer_ticker":"ITCI","issuer_name_source":null,"issuer_url":"/issuer/0001567514","owner_cik":"0001585699","owner_name":"Mates Sharon","owner_display_name":"Mates Sharon","owner_url":"/insider/0001585699","role":"Director, Officer (Chairman, President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chairman, President & CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20565.0,"shares_display":"20,565","price_per_share":65.2138526622903,"price_display":"65.21","price_state":"stated","total_value":1341122.88,"total_display":"1,341,122.88","total_whole":"1,341,123","shares_owned_after":1056333.0,"shares_owned_after_display":"1,056,333","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-03-11","filed_date":"2024-03-11","scope":"insider","n_lines":4},{"id":2543770,"accession":"0000950170-24-029583","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-029583","line_url":"/filing/0000950170-24-029583","is_derivative":false,"issuer_cik":"0001567514","issuer_name":"Intra-Cellular Therapies, Inc.","issuer_ticker":"ITCI","issuer_name_source":null,"issuer_url":"/issuer/0001567514","owner_cik":"0001585699","owner_name":"Mates Sharon","owner_display_name":"Mates Sharon","owner_url":"/insider/0001585699","role":"Director, Officer (Chairman, President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chairman, President & CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":40712.0,"shares_display":"40,712","price_per_share":66.49826242876793,"price_display":"66.50","price_state":"stated","total_value":2707277.26,"total_display":"2,707,277.26","total_whole":"2,707,277","shares_owned_after":1059063.0,"shares_owned_after_display":"1,059,063","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-03-07","filed_date":"2024-03-11","scope":"insider","n_lines":2},{"id":2386864,"accession":"0000950170-24-021568","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000950170-24-021568","line_url":"/filing/0000950170-24-021568","is_derivative":false,"issuer_cik":"0001567514","issuer_name":"Intra-Cellular Therapies, Inc.","issuer_ticker":"ITCI","issuer_name_source":null,"issuer_url":"/issuer/0001567514","owner_cik":"0001585699","owner_name":"Mates Sharon","owner_display_name":"Mates Sharon","owner_url":"/insider/0001585699","role":"Director, Officer (Chairman, President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chairman, President & CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":22590.0,"shares_display":"22,590","price_per_share":69.78594156706507,"price_display":"69.79","price_state":"stated","total_value":1576464.42,"total_display":"1,576,464.42","total_whole":"1,576,464","shares_owned_after":1050309.0,"shares_owned_after_display":"1,050,309","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-26","filed_date":"2024-02-27","scope":"insider","n_lines":3},{"id":3108249,"accession":"0000950170-24-011398","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-24-011398","line_url":"/filing/0000950170-24-011398","is_derivative":false,"issuer_cik":"0001567514","issuer_name":"Intra-Cellular Therapies, Inc.","issuer_ticker":"ITCI","issuer_name_source":null,"issuer_url":"/issuer/0001567514","owner_cik":"0001585699","owner_name":"Mates Sharon","owner_display_name":"Mates Sharon","owner_url":"/insider/0001585699","role":"Director, Officer (Chairman, President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chairman, President & CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":33885.0,"shares_display":"33,885","price_per_share":67.07078353253652,"price_display":"67.07","price_state":"stated","total_value":2272693.5,"total_display":"2,272,693.50","total_whole":"2,272,694","shares_owned_after":1050309.0,"shares_owned_after_display":"1,050,309","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-02","filed_date":"2024-02-05","scope":"insider","n_lines":2},{"id":2458284,"accession":"0000950170-24-005557","txn_seq":10,"anchor":"line-10","filing_url":"/filing/0000950170-24-005557","line_url":"/filing/0000950170-24-005557","is_derivative":false,"issuer_cik":"0001567514","issuer_name":"Intra-Cellular Therapies, Inc.","issuer_ticker":"ITCI","issuer_name_source":null,"issuer_url":"/issuer/0001567514","owner_cik":"0001585699","owner_name":"Mates Sharon","owner_display_name":"Mates Sharon","owner_url":"/insider/0001585699","role":"Director, Officer (Chairman, President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chairman, President & CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":67917.0,"shares_display":"67,917","price_per_share":65.19499433131617,"price_display":"65.19","price_state":"stated","total_value":4427848.43,"total_display":"4,427,848.43","total_whole":"4,427,848","shares_owned_after":1050629.0,"shares_owned_after_display":"1,050,629","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-18","filed_date":"2024-01-18","scope":"insider","n_lines":2},{"id":2458273,"accession":"0000950170-24-005557","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0000950170-24-005557","line_url":"/filing/0000950170-24-005557","is_derivative":false,"issuer_cik":"0001567514","issuer_name":"Intra-Cellular Therapies, Inc.","issuer_ticker":"ITCI","issuer_name_source":null,"issuer_url":"/issuer/0001567514","owner_cik":"0001585699","owner_name":"Mates Sharon","owner_display_name":"Mates Sharon","owner_url":"/insider/0001585699","role":"Director, Officer (Chairman, President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chairman, President & CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":48084.0,"shares_display":"48,084","price_per_share":66.23953206887946,"price_display":"66.24","price_state":"stated","total_value":3185061.66,"total_display":"3,185,061.66","total_whole":"3,185,062","shares_owned_after":1067760.0,"shares_owned_after_display":"1,067,760","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-17","filed_date":"2024-01-18","scope":"insider","n_lines":2},{"id":2458261,"accession":"0000950170-24-005557","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000950170-24-005557","line_url":"/filing/0000950170-24-005557","is_derivative":false,"issuer_cik":"0001567514","issuer_name":"Intra-Cellular Therapies, Inc.","issuer_ticker":"ITCI","issuer_name_source":null,"issuer_url":"/issuer/0001567514","owner_cik":"0001585699","owner_name":"Mates Sharon","owner_display_name":"Mates Sharon","owner_url":"/insider/0001585699","role":"Director, Officer (Chairman, President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chairman, President & CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":75361.0,"shares_display":"75,361","price_per_share":67.24940048566235,"price_display":"67.25","price_state":"stated","total_value":5067982.07,"total_display":"5,067,982.07","total_whole":"5,067,982","shares_owned_after":1056191.0,"shares_owned_after_display":"1,056,191","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-16","filed_date":"2024-01-18","scope":"insider","n_lines":3},{"id":8753445,"accession":"0001209191-23-050101","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-23-050101","line_url":"/filing/0001209191-23-050101#line-3","is_derivative":false,"issuer_cik":"0001567514","issuer_name":"Intra-Cellular Therapies, Inc.","issuer_ticker":"ITCI","issuer_name_source":null,"issuer_url":"/issuer/0001567514","owner_cik":"0001585699","owner_name":"Mates Sharon","owner_display_name":"Mates Sharon","owner_url":"/insider/0001585699","role":"Director, Officer (Chairman, President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chairman, President & CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":44413.0,"shares_display":"44,413","price_per_share":54.17,"price_display":"54.17","price_state":"stated","total_value":2405852.21,"total_display":"2,405,852.21","total_whole":"2,405,852","shares_owned_after":1050309.0,"shares_owned_after_display":"1,050,309","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-09-19","filed_date":"2023-09-19","scope":"insider"},{"id":8753442,"accession":"0001209191-23-050101","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-050101","line_url":"/filing/0001209191-23-050101","is_derivative":false,"issuer_cik":"0001567514","issuer_name":"Intra-Cellular Therapies, Inc.","issuer_ticker":"ITCI","issuer_name_source":null,"issuer_url":"/issuer/0001567514","owner_cik":"0001585699","owner_name":"Mates Sharon","owner_display_name":"Mates Sharon","owner_url":"/insider/0001585699","role":"Director, Officer (Chairman, President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chairman, President & CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":55587.0,"shares_display":"55,587","price_per_share":53.75740083112958,"price_display":"53.76","price_state":"stated","total_value":2988212.64,"total_display":"2,988,212.64","total_whole":"2,988,213","shares_owned_after":1094722.0,"shares_owned_after_display":"1,094,722","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-09-18","filed_date":"2023-09-19","scope":"insider","n_lines":2},{"id":8744389,"accession":"0001209191-23-018283","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001209191-23-018283","line_url":"/filing/0001209191-23-018283","is_derivative":false,"issuer_cik":"0001567514","issuer_name":"Intra-Cellular Therapies, Inc.","issuer_ticker":"ITCI","issuer_name_source":null,"issuer_url":"/issuer/0001567514","owner_cik":"0001585699","owner_name":"Mates Sharon","owner_display_name":"Mates Sharon","owner_url":"/insider/0001585699","role":"Director, Officer (Chairman, President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chairman, President & CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20565.0,"shares_display":"20,565","price_per_share":44.992712861658156,"price_display":"44.99","price_state":"stated","total_value":925275.14,"total_display":"925,275.14","total_whole":"925,275","shares_owned_after":1131721.0,"shares_owned_after_display":"1,131,721","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-03-13","filed_date":"2023-03-13","scope":"insider","n_lines":2},{"id":8744380,"accession":"0001209191-23-018283","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-23-018283","line_url":"/filing/0001209191-23-018283","is_derivative":false,"issuer_cik":"0001567514","issuer_name":"Intra-Cellular Therapies, Inc.","issuer_ticker":"ITCI","issuer_name_source":null,"issuer_url":"/issuer/0001567514","owner_cik":"0001585699","owner_name":"Mates Sharon","owner_display_name":"Mates Sharon","owner_url":"/insider/0001585699","role":"Director, Officer (Chairman, President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chairman, President & CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":41770.0,"shares_display":"41,770","price_per_share":43.15455470433325,"price_display":"43.15","price_state":"stated","total_value":1802565.75,"total_display":"1,802,565.75","total_whole":"1,802,566","shares_owned_after":1137114.0,"shares_owned_after_display":"1,137,114","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-03-10","filed_date":"2023-03-13","scope":"insider","n_lines":2},{"id":8182822,"accession":"0001209191-23-013434","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-23-013434","line_url":"/filing/0001209191-23-013434#line-3","is_derivative":false,"issuer_cik":"0001567514","issuer_name":"Intra-Cellular Therapies, Inc.","issuer_ticker":"ITCI","issuer_name_source":null,"issuer_url":"/issuer/0001567514","owner_cik":"0001585699","owner_name":"Mates Sharon","owner_display_name":"Mates Sharon","owner_url":"/insider/0001585699","role":"Director, Officer (Chairman, President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chairman, President & CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":22590.0,"shares_display":"22,590","price_per_share":47.03,"price_display":"47.03","price_state":"stated","total_value":1062407.7,"total_display":"1,062,407.70","total_whole":"1,062,408","shares_owned_after":1100309.0,"shares_owned_after_display":"1,100,309","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-24","filed_date":"2023-02-27","scope":"insider"},{"id":8182784,"accession":"0001209191-23-011982","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-23-011982","line_url":"/filing/0001209191-23-011982","is_derivative":false,"issuer_cik":"0001567514","issuer_name":"Intra-Cellular Therapies, Inc.","issuer_ticker":"ITCI","issuer_name_source":null,"issuer_url":"/issuer/0001567514","owner_cik":"0001585699","owner_name":"Mates Sharon","owner_display_name":"Mates Sharon","owner_url":"/insider/0001585699","role":"Director, Officer (Chairman, President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chairman, President & CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":27848.0,"shares_display":"27,848","price_per_share":46.82563559322034,"price_display":"46.83","price_state":"stated","total_value":1304000.3,"total_display":"1,304,000.30","total_whole":"1,304,000","shares_owned_after":1105262.0,"shares_owned_after_display":"1,105,262","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-21","filed_date":"2023-02-22","scope":"insider","n_lines":4}],"collapsed":true,"next_cursor":"2023-02-21|8182781","ledger_fault":false,"count":{"value":92,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":92,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":92},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001567514","name":"Intra-Cellular Therapies, Inc.","url":"/issuer/0001567514","role":"Director, Officer (Chairman and CEO)","n_filings":33,"first_seen":"2014-11-28","last_seen":"2024-12-06"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001585699","retrieved_at":"2026-08-24T08:36:29+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}